Results 81 to 90 of about 132,778 (287)

A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated With Colchicine Prophylaxis

Arthritis &Rheumatology, EarlyView.
Objective This study investigated that serum metabolomics, before urate‐lowering therapy (ULT) initiation, could serve as a biomarker for responsiveness to colchicine prophylaxis in patients with gout commencing treat‐to‐target ULT. Methods We studied a multicenter prospective cohort (n = 409) initiating treat‐to‐target ULT plus colchicine prophylaxis.
Wenyan Sun, Lingfang Xu, Haibing Chen, Mingshu Sun, Zhiqiang Li, Rui Li, Lidan Ma, Hui Zhang, Aichang Ji, Yuwei He, Na Wu, Le Yan, Robert Terkeltaub, Changgui Li   +13 more
wiley   +1 more source

A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose

The Turkish Journal of Gastroenterology
Background/Aims: Nonalcoholic fatty liver disease is considered as the hepatic manifestation of metabolic syndrome. Detection of circulating exosomes together with metabolomic analysis of their cargo would provide early signals for metabolic derangements
Weiyun Jiang, Qiaofei Jin, Chunqing Li, Yunhao Xun   +3 more
doaj   +1 more source

Pediatric nonalcoholic fatty liver disease

Jornal de Pediatria, 2019
n ...
Chiesa Claudio, Andreoli Gian Marco, Pacifico Lucia   +2 more
openaire   +7 more sources

Genome-Wide Association Study Identifies Loci for Liver Enzyme Concentrations in Mexican Americans: The GUARDIAN Consortium. [PDF]

, 2019
ObjectivePopulations of Mexican American ancestry are at an increased risk for nonalcoholic fatty liver disease. The objective of this study was to determine whether loci in known and novel genes were associated with variation in aspartate ...
Chen, Yii-Der I, Fingerlin, Tasha E, Goodarzi, Mark O, Guo, Xiuqing, Langefeld, Carl D, Norris, Jill M, Palmer, Nicholette D, Raffel, Leslie J, Rotter, Jerome I, Taylor, Kent D, Wagenknecht, Lynne E, Wang, Nan, Watanabe, Richard M, Williams, Adrienne H, Xiang, Anny H, Young, Kendra A   +15 more
core   +2 more sources

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Arthritis &Rheumatology, EarlyView.
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +14 more
wiley   +1 more source

Nonalcoholic Fatty Liver Disease in Children [PDF]

Seminars in Liver Disease, 2018
AbstractNonalcoholic steatohepatitis, a progressive form of nonalcoholic fatty liver disease (NAFLD), is one of the most common hepatic diseases in children who present with particular risk factors including obesity, sedentary lifestyle, and/or a predisposing genetic background.
Mann, Jake P., Valenti, Luca, Scorletti, Eleonora, Byrne, Christopher D., Nobili, Valerio   +4 more
openaire   +6 more sources

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression [PDF]

, 2018
The complete mechanism accounting for the progression from simple steatosis to steatohepatitis in nonalcoholic fatty liver disease (NAFLD) has not been elucidated.
Avolio, Carlo, Bellanti, Francesco, Blonda, Maria, di Bello, Giorgia, Facciorusso, Antonio, Iannelli, Giuseppina, Iuliano, Luigi, Poli, Giuseppe, Serviddio, Gaetano, Tamborra, Rosanna, Vendemiale, Gianluigi, Villani, Rosanna   +11 more
core   +2 more sources

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Role of nonalcoholic fatty liver disease in hepatocellular carcinoma

Annals of Hepatology, 2009
Obesity and related disorders are a common cause of morbidity worldwide. Nonalcoholic fatty liver disease is the most important hepatic consequence of adipose accumulation.
Norberto C. Chávez-Tapia, Nahum Méndez-Sánchez, Misael Uribe   +2 more
doaj   +1 more source